The Rapacious Enrichment Of Gilead Sciences, Inc.'s CEO

free biotech news

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The statutory rape of shareholders by public companies’ managements is awesome and continuous. But, carefully manicured compensation guidelines in proxy statements apparently meet standards that preclude interference by the SEC. Pillage varies directly with the thickness of the proxy document itself. Shareholders rarely vote against “full package” largesse. Institutions look the other way just so long as the stock outperforms.

Hey, check out all the research scientist jobs. Post your resume today!

MORE ON THIS TOPIC